Merck's chronic cough med gets a nay from FDA, potentially clearing first-to-market path for Bellus

Retrieved on: 2022-01-24 15:59:46

Tags for this article:

Click the tags to see associated articles and topics

Merck's chronic cough med gets a nay from FDA, potentially clearing first-to-market path for Bellus. View article details on hiswai:

Excerpt

... room for competitor Bellus Health in a first-to-market battle. ... the gap for Bellus' BLU-5937, RBC Capital Markets analysts wrote in a note.

Article found on: www.fiercebiotech.com